Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | RORC | P51449 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.35 |
| ▸ | NTRK1 | P04629 | 4/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.34 |
| ▸ | EIF4E | P06730 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2444826 | 0.86 | ATR (0.37) | NPSR1LMNAMEN1KMT2ANR3C1 | |
| SCHEMBL2451920 | 0.85 | NPSR1 (0.46) | NPSR1LMNAPKMPOLBBLM | |
| SCHEMBL2446534 | 0.84 | NPSR1 (0.47) | NPSR1LMNAPKMRORCPOLB | |
| SCHEMBL2445371 | 0.82 | NPSR1 (0.45) | NPSR1LMNAPKMRORCMEN1 | |
| SCHEMBL2450124 | 0.78 | NPSR1 (0.42) | NPSR1LMNAPKMRORCPOLB | |
| SCHEMBL2444858 | 0.78 | RORC (0.38) | RORCMEN1KMT2AMAPTCRHR1 | |
| SCHEMBL2448276 | 0.78 | NPSR1 (0.48) | NPSR1LMNAPKMPOLBMEN1 | |
| SCHEMBL2442222 | 0.75 | NPSR1 (0.52) | NPSR1LMNAPKMPOLBBLM | |
| SCHEMBL2447842 | 0.72 | USP1 (0.43) | LMNAPOLBNR3C1MAPT | |
| SCHEMBL2444558 | 0.70 | RAF1 (0.37) | LMNARORCPOLBKMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110218197-A1 | SUBSTITUTED AZA-BICYCLIC IMIDAZOLE DERIVATIVES USEFUL AS TRPM8 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110218197-A1 | SUBSTITUTED AZA-BICYCLIC IMIDAZOLE DERIVATIVES USEFUL AS TRPM8 RECEPTOR MODULATORS | TRPM8, TRPV1, TRPA1 | NPSR1 481/4885LMNA 3487/4885PKM 2263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.